---
title: "GlucoTrack | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286471735.md"
datetime: "2026-05-14T21:29:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286471735.md)
  - [en](https://longbridge.com/en/news/286471735.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286471735.md)
---

# GlucoTrack | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -2.65.

EBIT: As of FY2026 Q1, the actual value is USD -4.203 M.

#### Operating Expenses

-   Research and Development Expenses for GlucoTrack, Inc. were $2.1 million for the first quarter of 2026, an increase of $0.2 million from $1.9 million in the first quarter of 2025.
-   General and Administrative Expenses were $2.1 million for the first quarter of 2026, up $0.5 million from $1.6 million in the first quarter of 2025.

#### Other (Income) Expense, Net

-   Other expense was $0.1 million for the first quarter of 2026, a decrease from $3.3 million in the first quarter of 2025.

#### Net Loss

-   Net loss for the first quarter of 2026 was -$4.3 million, a decrease from a net loss of -$6.8 million for the first quarter of 2025.

#### Cash Flow and Position

-   Cash and cash equivalents as of March 31, 2026, were $3.9 million, down from $7.4 million as of December 31, 2025.
-   The net decrease in cash and cash equivalents was due to -$4.1 million of cash used in operating activities, partially offset by $0.6 million in net proceeds from financing activities.
-   The Company reduced the outstanding balance of its $3.6 million promissory note to approximately $1.6 million.
-   Subsequent to quarter end, GlucoTrack, Inc. drew approximately $1.0 million under its existing equity line of credit facility.

#### Operational Metrics

-   GlucoTrack, Inc. submitted its Investigational Device Exemption (IDE) application to the FDA to initiate a U.S. clinical study for its fully implantable continuous blood glucose monitoring (CBGM) technology.
-   Two peer-reviewed articles were published, one validating the long-term stability of its glucose oxidase sensor in the _IEEE Sensors Journal_, and another demonstrating the long-term accuracy and stability of the fully implantable CBGM system in an _in-vivo_ ovine study with a 6.8% Mean Absolute Relative Difference (MARD) in _The Journal of Diabetes Research_.

#### Outlook / Guidance

-   GlucoTrack, Inc. is targeting the launch of its U.S. clinical trial in the second half of 2026 and plans to present clinical data at industry conferences as it becomes available. The Company anticipates its existing cash and cash equivalents will provide sufficient runway into early Q3 2026, enabling the initiation of its U.S. human clinical trial shortly thereafter.

### Related Stocks

- [GCTK.US](https://longbridge.com/en/quote/GCTK.US.md)

## Related News & Research

- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md)
- [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md)
- [XP Inc. Reports First Quarter 2026 Results | XP Stock News](https://longbridge.com/en/news/286814239.md)